Navigation Links
Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
Date:7/11/2013

KANSAS CITY, Kan. and BOSTON, July 11, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative prescription medications for pets, today announced the full exercise of the over-allotment option granted to the underwriters to purchase 862,500 additional shares of common stock, at a public offering price of $6.00 per share, in connection with its previously announced initial public offering of 5,750,000 shares of common stock that closed on July 2, 2013, bringing the total gross proceeds from the offering to $39,675,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.  The company's common stock is listed on The NASDAQ Global Market under the trading symbol "PETX."

Stifel and Lazard Capital Markets acted as lead book-running managers for the offering.  William Blair, JMP Securities and Craig-Hallum Capital Group acted as co-managers.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 26, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

The offering is being made only by means of a written prospectus forming part of the effective registration statement.  Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by callin
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
7. Nile Therapeutics Reports 2011 Third Quarter Financial Results
8. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
9. Fate Therapeutics Strengthens Its iPSC Platform
10. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
11. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... - Researchers are making progress in creating digital transistors ... thought to dramatically limit the material,s use in computers ... of carbon that conducts electricity with little resistance or ... earned a Nobel Prize in physics - it was ...
... was named by FierceBiotech today as one of 2011,s ... promising private biotechnology companies in the industry. This is FierceBiotech,s ... has done a super job of raising the funds and ... combination therapy – toward the market," says Ryan McBride, the ...
... Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 ... today that data from two studies, a Phase II ... compound custirsen (OGX-011/TV-1011), were published in the September issues ... Cancer Research . Custirsen inhibits ...
Cached Biology Technology:Innovation is step toward digital graphene transistors 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 2FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 2OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 3OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 4OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals 5
(Date:9/18/2014)... of carbon and nitrogen comprise all spheres of ... systems have caused imbalances and perturbations that resulted ... Increased GHGs result in climate changes which influence ... and the atmosphere. Understanding these feedback mechanisms has ... environmental science during the past three decades. , ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... is probably the ultimate form of camouflage: you don,t ... this strategy is not as uncommon as you might ... County, USA, explains that the larval life stages of ... part of the anatomy that most creatures cannot make ... have to shield each individual eye unit with an ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... Bethesda, MD This FASEB Science Research Conference ... of intestinal lipid digestion and absorption with new ... to understanding the mechanisms of health maintenance and ... resistance and diabetes, dyslipidemia, intestinal failure and gastrointestinal ...
... Conference focuses on recent advances in the methods for ... to promote the discovery and exchange of new methods ... facilitate the application of methods in protein structure analysis ... to support and foster the education of researchers in ...
... from Iowa State University (USA) published a study which ... metals. Now, a team from the University of the ... results throw this discovery into question. This has reaffirmed ... validity in the press. The resistance and elasticity ...
Cached Biology News:Spider silk ties scientists up in knots 2
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: